While in DRE it remains currently unclear how the cKD works despite a much better understanding of anticonvulsant mechanisms [4], in the GLUT1-DS and PDCD it is the treatment of choice in order to switch brain metabolism from glucose to ketone bodies (KBs) and leading to a powerful improvement in neurologic symptoms. This evidence concerns the gene SLC2A1 and chronic kidney disease.